BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 10350032)

  • 1. Controlled trial of high doses of pemoline for adults with attention-deficit/hyperactivity disorder.
    Wilens TE; Biederman J; Spencer TJ; Frazier J; Prince J; Bostic J; Rater M; Soriano J; Hatch M; Sienna M; Millstein RB; Abrantes A
    J Clin Psychopharmacol; 1999 Jun; 19(3):257-64. PubMed ID: 10350032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pemoline treatment of adolescents with attention deficit hyperactivity disorder: a short-term controlled trial.
    Bostic JQ; Biederman J; Spencer TJ; Wilens TE; Prince JB; Monuteaux MC; Sienna M; Polisner DA; Hatch M
    J Child Adolesc Psychopharmacol; 2000; 10(3):205-16. PubMed ID: 11052410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pemoline effects on children with ADHD: a time-response by dose-response analysis on classroom measures.
    Pelham WE; Swanson JM; Furman MB; Schwindt H
    J Am Acad Child Adolesc Psychiatry; 1995 Nov; 34(11):1504-13. PubMed ID: 8543519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized controlled trial of pemoline for attention-deficit/hyperactivity disorder in substance-abusing adolescents.
    Riggs PD; Hall SK; Mikulich-Gilbertson SK; Lohman M; Kayser A
    J Am Acad Child Adolesc Psychiatry; 2004 Apr; 43(4):420-9. PubMed ID: 15187802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Six-week, double-blind, placebo-controlled study of desipramine for adult attention deficit hyperactivity disorder.
    Wilens TE; Biederman J; Prince J; Spencer TJ; Faraone SV; Warburton R; Schleifer D; Harding M; Linehan C; Geller D
    Am J Psychiatry; 1996 Sep; 153(9):1147-53. PubMed ID: 8780417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of SHP465 Mixed Amphetamine Salts in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults: Results of a Randomized, Double-Blind, Placebo-Controlled, Forced-Dose Clinical Study.
    Weisler RH; Greenbaum M; Arnold V; Yu M; Yan B; Jaffee M; Robertson B
    CNS Drugs; 2017 Aug; 31(8):685-697. PubMed ID: 28712074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An open trial of pemoline in drug-dependent delinquents with attention-deficit hyperactivity disorder.
    Riggs PD; Thompson LL; Mikulich SK; Whitmore EA; Crowley TJ
    J Am Acad Child Adolesc Psychiatry; 1996 Aug; 35(8):1018-24. PubMed ID: 8755798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Double-Blind, Placebo-Controlled, Phase II Study to Determine the Efficacy, Safety, Tolerability and Pharmacokinetics of a Controlled Release (CR) Formulation of Mazindol in Adults with DSM-5 Attention-Deficit/Hyperactivity Disorder (ADHD).
    Wigal TL; Newcorn JH; Handal N; Wigal SB; Mulligan I; Schmith V; Konofal E
    CNS Drugs; 2018 Mar; 32(3):289-301. PubMed ID: 29557078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study.
    Biederman J; Swanson JM; Wigal SB; Kratochvil CJ; Boellner SW; Earl CQ; Jiang J; Greenhill L
    Pediatrics; 2005 Dec; 116(6):e777-84. PubMed ID: 16322134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
    CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pemoline in adult attention deficit hyperactivity disorder: predictors of nonresponse.
    Heiligenstein E; Anders J
    J Am Coll Health; 1997 Mar; 45(5):225-9. PubMed ID: 9069682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blood pressure changes associated with medication treatment of adults with attention-deficit/hyperactivity disorder.
    Wilens TE; Hammerness PG; Biederman J; Kwon A; Spencer TJ; Clark S; Scott M; Podolski A; Ditterline JW; Morris MC; Moore H
    J Clin Psychiatry; 2005 Feb; 66(2):253-9. PubMed ID: 15705013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.
    Adler LA; Zimmerman B; Starr HL; Silber S; Palumbo J; Orman C; Spencer T
    J Clin Psychopharmacol; 2009 Jun; 29(3):239-47. PubMed ID: 19440077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, fixed-dose study followed by abrupt discontinuation.
    Swanson JM; Greenhill LL; Lopez FA; Sedillo A; Earl CQ; Jiang JG; Biederman J
    J Clin Psychiatry; 2006 Jan; 67(1):137-47. PubMed ID: 16426100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR™) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Phase III, Randomized, Double-Blind Study.
    Wigal SB; Nordbrock E; Adjei AL; Childress A; Kupper RJ; Greenhill L
    CNS Drugs; 2015 Apr; 29(4):331-40. PubMed ID: 25877989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of once-daily and divided doses of modafinil in children with attention-deficit/hyperactivity disorder: a randomized, double-blind, and placebo-controlled study.
    Biederman J; Swanson JM; Wigal SB; Boellner SW; Earl CQ; Lopez FA;
    J Clin Psychiatry; 2006 May; 67(5):727-35. PubMed ID: 16841622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of a novel biphasic controlled-release methylphenidate formula in adults with attention-deficit/hyperactivity disorder: results of a double-blind, placebo-controlled crossover study.
    Jain U; Hechtman L; Weiss M; Ahmed TS; Reiz JL; Donnelly GA; Harsanyi Z; Darke AC
    J Clin Psychiatry; 2007 Feb; 68(2):268-77. PubMed ID: 17335326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of attention-deficit/hyperactivity disorder.
    Jadad AR; Boyle M; Cunningham C; Kim M; Schachar R
    Evid Rep Technol Assess (Summ); 1999 Nov; (11):i-viii, 1-341. PubMed ID: 10790990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extended-Release Mixed Amphetamine Salts vs Placebo for Comorbid Adult Attention-Deficit/Hyperactivity Disorder and Cocaine Use Disorder: A Randomized Clinical Trial.
    Levin FR; Mariani JJ; Specker S; Mooney M; Mahony A; Brooks DJ; Babb D; Bai Y; Eberly LE; Nunes EV; Grabowski J
    JAMA Psychiatry; 2015 Jun; 72(6):593-602. PubMed ID: 25887096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.